文献速递临床免疫分子诊断质量管理与危急值

循环CHI3L1/YKL-40在肺癌中的生物标志物潜力、分析挑战与临床转化前景

Circulating CHI3L1/YKL-40 in lung cancer: Biomarker potential, analytical challenges, and clinical translation prospects.
PubMed 文献 · Clin Chim Acta · 2026-05-23

本文综述循环CHI3L1/YKL-40作为肺癌生物标志物的潜力。两项荟萃分析(n>950例患者)验证血清CHI3L1升高是非小细胞肺癌(HR=2.23)和小细胞肺癌(HR=1.45)不良生存的独立预测因子。但COPD等炎症疾病可致假阳性,需疾病特异性参考区间校正,且需解决分析前处理、ELISA平台差异等技术问题。

要点

  • 血清CHI3L1升高是非小细胞肺癌(HR=2.23)和小细胞肺癌(HR=1.45)不良生存的独立预测因子。
  • COPD等炎症疾病可显著导致CHI3L1假阳性,需采用疾病特异性参考区间校正。
  • CHI3L1预测免疫检查点抑制剂反应仅有初步证据,需前瞻性研究验证。

核心结论

  • CHI3L1/YKL-40是生物学合理、处于研究阶段且可能具有临床相关性的循环肺癌标志物。

研究设计与样本

  • 综述,汇总两项荟萃分析(n>950例患者)及初步证据,提出转化框架。

主要发现

  • 两项荟萃分析(n>950例患者)验证血清CHI3L1升高是非小细胞肺癌(HR=2.23)和小细胞肺癌(HR=1.45)不良生存的独立预测因子。
  • 有初步证据表明CHI3L1可预测免疫检查点抑制剂反应,但需前瞻性研究验证。
  • COPD和其他炎症性疾病中CHI3L1升高显著贡献假阳性结果,需疾病特异性参考区间校正。

关键数值与推荐

  • 非小细胞肺癌不良生存独立预测HR=2.23。
  • 小细胞肺癌不良生存独立预测HR=1.45。

临床怎么用

  • 需解决分析前样本处理、ELISA平台间变异、年龄和COPD等生物学影响及CHI3L1启动子SNP(rs4950928)等技术问题。
  • 提出转化框架:标准化多分析平台、开展多中心前瞻性研究、获得体外诊断工具监管批准。

局限性

  • CHI3L1预测免疫检查点抑制剂反应仅有初步证据,需前瞻性研究验证。
  • COPD等炎症疾病可致假阳性,需疾病特异性参考区间校正。
  • 需解决分析前处理、ELISA平台差异、年龄和COPD等生物学影响及CHI3L1启动子SNP(rs4950928)等技术问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer is the leading cause of cancer-related mortality worldwide, primarily due to inadequate early detection, which consequently leads to poor overall survival rates. Current serum tumor markers, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (ProGRP), exhibit limitations in terms of sensitivity, specificity, and predictive value for immunotherapy. The secreted glycoprotein chitinase-3-like protein 1 (CHI3L1/YKL-40), detectable by ELISA in serum and plasma, is a biologically plausible, research-stage, and potentially clinically relevant circulating lung cancer marker. Two meta-analyses (n > 950 patients) validated that elevated serum CHI3L1 is an independent predictor of poor survival in non-small cell (HR = 2.23) and small cell (HR = 1.45) lung cancer. There is preliminary evidence that it can predict the response to immune checkpoint inhibitors; however, this needs to be validated in a prospective study. Elevated levels of CHI3L1 in chronic obstructive pulmonary disease (COPD) and other inflammatory disorders significantly contribute to false-positive results, necessitating the use of disease-specific reference intervals for correction. To establish CHI3L1 as a clinical biomarker, it is imperative to address key technical issues, including pre-analytical sample handling, variability across ELISA platforms, biological influences such as age and chronic obstructive pulmonary disease, and the CHI3L1 promoter single nucleotide polymorphism (SNP) (rs4950928). A translational framework is proposed, which involves the standardization of multi-analytical platforms, the conduct of multi-center prospective studies, and the attainment of regulatory approval as an in vitro diagnostic tool.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Omer AB, Saleem S, Khan R, et al. Circulating CHI3L1/YKL-40 in lung cancer: Biomarker potential, analytical challenges, and clinical translation prospects. Clin Chim Acta. 2026. PMID: 42177966. doi:10.1016/j.cca.2026.121112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。